Redeye strengthens its positive view of CombinedX following a robust Q4 report with strong organic g...
Redeye provides a first comment on the back of XMReality’s Q4 report.
ARR +10% y-o-y, +3% vs ABGSCe Cons. likely to make pos.
Redeye provides an initial take on Arise’s Q4 report.
Mestro reported a strong quarter with accelerating growth numbers underpinned by some larger contrac...
Redeye provides an initial take on SenzaGen’s H2 2022 report.
EBITDA SEK 52m vs. ABGSCe SEK 66m Average realized price of SEK 850/MWh vs.
Redeye provides an initial take on BONESUPPORT’s Q4 results, and we are encouraged by the company be...
Redeye's first comments on the Q4 report this morning.
Q4 NOI +29% y-o-y, +14% vs ABGSCe Property values -0.
Wants to implement licensing model for Functional Wood Cash position still slim at SEK 15m, but up f...
Redeye comments on Sozap’s Q4 results, which came in lower than expected in terms of sales and profi...
Redeye provides an initial take on Sedana Medical’s Q4 results, and we are optimistic about the sale...
Vitrolife is in good health and the company ended 2022 on a strong finish and a positive outlook ahe...
Taaleri reported Q4 EBIT of EUR 7.1m, coming 24% below Refinitiv consensus at EUR 9.
Redeye is quite surprised by the news that OXE Marine has developed the OXE Hybrid 450, a new diesel...
Q4 net sales came in 1% above our estimate, but clean EBIT was 7% below our expectation.
Redeye raises its Base Case and forecasts slightly following a solid Q4 report showing high organic ...
Redeye strengthens its positive view of Formpipe following the solid Q4 report showing a record-high...
Solid Q4, but we trim '23e adj. EBITDA by 4% Exciting plans for a separate listing can unlock value ...
